New golden era of chelation therapy in thalassaemia: The achievement and maintenance of normal range body iron stores. Response to Kontoghiorghes et al

British Journal of Haematology

Volumn 150, Issue 4, 2010, Pages 491-

  Farmaki, Kallistheni ^a   Tzoumari, Ioanna ^a   Pappa, Christina ^a   Chouliaras, Giorgos ^b   Berdoukas, Vasilios ^b  

^a General Hospital of Corinth   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

chelation; iron overload; thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

BLOOD TRANSFUSION; CHELATION THERAPY; DISEASE COURSE; HUMAN; IRON STORAGE; LETTER; LIVER CANCER; LIVER FIBROSIS; PRIORITY JOURNAL; RISK FACTOR; THALASSEMIA;

EID: 77955143621     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08233.x     Document Type: Letter

References (5)

1. Borgna-Pignatti, C., Vergine, G., Lombardo, T., Cappellini, M.D., Cianciulli, P., Maggio, A., Renda, D., Lai, M.E., Mandas, A., Forni, G., Piga, A. Bisconte, M.G. (2004) Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 124, 114 117.
2. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. Cabantchik, Z.I. (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, 102, 2670 2677.
3. Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G. Berdoukas, V. (2010) Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Haematology, 148, 466 475.
4. Ko, C., Siddaiah, N., Berger, J., Gish, R., Brandhagen, D., Sterling, R.K., Cotler, S.J., Fontana, R.J., McCashland, T.M., Han, S.H., Gordon, F.D., Schilsky, M.L. Kowdley, K.V. (2007) Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver International, 27, 1394 1401.
5. Kontoghiorghes, G.J. Kolnagou, A. (2006) Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica, 91, ELT04.